By Keith Loria

Executive Overview

For decades, a diagnosis of feline infectious peritonitis (FIP) carried an emotional and clinical finality. Once considered nearly uniformly fatal, this devastating disease of domestic and wild felines can now be effectively treated with modern antiviral therapies. This revolutionary shift from a palliative paradigm to a curative one has fundamentally altered veterinary medicine. However, a profound clinical paradox has emerged in its wake: while veterinarians finally possess the pharmacological tools to save FIP patients, they still lack a single, flawless, antemortem diagnostic test capable of definitively confirming or excluding the disease across every presentation.

Enter a groundbreaking diagnostic study led by researchers at Colorado State University (CSU). The investigative team has evaluated multiplex fluorescent immunocytochemistry (MF-ICC)—an advanced assay designed to detect feline coronavirus antigen within macrophages, the cellular epicenter of systemic FIP—without requiring an invasive surgical biopsy. While proving to be the most accurate methodology among several compared in the trial, experts emphasize that MF-ICC is not a standalone "silver bullet." Instead, diagnosing FIP remains a sophisticated exercise in clinical detective work, demanding an amalgamation of clinical signs, biochemical markers, and complementary assays. As the stakes of accurate diagnosis skyrocket in the era of effective treatments, the development of integrated diagnostic systems like MF-ICC represents a critical step forward for veterinary practitioners navigating the high-pressure landscape of feline internal medicine.

Detailed Chronology: The Evolution of FIP Diagnostics and Treatment

The historical trajectory of feline infectious peritonitis has undergone a radical transformation over the past ten years. Historically, veterinary clinicians approached FIP with extreme diagnostic caution, knowing that confirmation offered little more than a recommendation for humane euthanasia. Because the disease presents in two distinct clinical forms—effusive ("wet") and noneffusive ("dry")—its identification has perpetually vexed pathologists and clinicians alike.

The Diagnostic Dilemma of the Noneffusive Form

While the effusive form of FIP often presents with characteristic abdominal or pleural fluid accumulation that can be readily sampled, the noneffusive form is notoriously cryptic. It frequently manifests as vague, non-specific systemic signs, including chronic fever, weight loss, lethargy, and ocular or neurological abnormalities.

"FIP is extremely diagnostically challenging, primarily in the noneffusive form," explains Samantha J.M. Evans, DVM, PhD, DACVP, DACVM, associate professor of clinical pathology at Colorado State University and lead author of the recent diagnostic study. "It’s much more important now to get a diagnosis, because we actually have treatment available."

Before the advent of nucleoside analog antivirals, a misdiagnosis carried heavy emotional weight but relatively limited therapeutic consequence, as options were minimal. Today, an incorrect or delayed diagnosis can mean the difference between life and death for a rapidly deteriorating patient. Conversely, empirical treatment of a non-FIP condition with expensive antivirals wastes valuable time, drains client finances, and exposes patients to unnecessary medications.

The Rise of MF-ICC: A Targeted Cellular Approach

To address these diagnostic roadblocks, Dr. Evans and an interdisciplinary team of collaborators turned their attention to multiplex fluorescent immunocytochemistry (MF-ICC). Feline coronavirus itself is ubiquitous, particularly in multi-cat households, catteries, and shelters. The vast majority of cats exposed to the enteric coronavirus never develop FIP. This high baseline exposure rate severely limits the utility of tests that merely confirm exposure.

Traditional diagnostics include:

• RT-PCR: Detects viral RNA, though it cannot consistently differentiate between non-pathogenic enteric coronavirus shedding and systemic FIP.
• Serology: Measures antibody titers against the virus, which often remains high in healthy, exposed populations.
• Serum Albumin-to-Globulin Ratio: Highlights biochemical shifts associated with systemic inflammation, serving as an indicator of suspicion rather than confirmation.
• Histopathology and Immunohistochemistry (IHC): Considered the historical gold standards for a definitive diagnosis, but they often require invasive surgical tissue biopsies that are risky or impossible in unstable, compromised patients.

MF-ICC circumvents these limitations by targeting the specific host cells driving the disease: macrophages. Using fluorescent antibodies, the assay detects both the feline coronavirus antigen and vimentin, a cellular marker unique to macrophages. By superimposing images captured at different wavelengths, the laboratory can verify whether the viral antigen is localized precisely inside the macrophage-like cells responsible for disseminating systemic FIP.

"The innovation we added was multiplexing [the viral marker] with another marker for cellular antigen called vimentin," Dr. Evans notes. "That cellular marker allows us to look specifically at macrophages, which are the hallmark cell type of FIP."

Co-author Benjamin Curtis, DVM, DACVP, clinical assistant professor at the University of Michigan’s Unit for Laboratory Animal Medicine Pathology Core, emphasizes the clinical utility of this dual-staining approach. "It’s minimally invasive," Dr. Curtis explains. "Pulling fluid out of the belly or doing a needle aspirate is much less invasive than needing to do a tissue biopsy. But then it brings in the gold-standard concept of immunohistochemistry, in that we can confirm there is viral antigen inside the cells that matches the presentation of FIP."

Supporting Context & Metrics: Trial Design and Findings

To rigorously evaluate the efficacy of MF-ICC, the research team designed a comprehensive clinical trial incorporating 84 feline patients. The cohort comprised 58 confirmed FIP cases and 26 control subjects diagnosed with alternative, non-FIP diseases. Final case determinations were firmly established via necropsy with histopathology and immunohistochemistry, documented response to targeted antiviral treatment, or rigorous clinical follow-up.

Comparative Performance Metrics

Researchers compared MF-ICC directly against three established modalities: RT-PCR, standard serology, and the serum albumin-to-globulin ratio. Using a conservative diagnostic threshold of at least one cell positive for both markers (viral antigen and vimentin), MF-ICC yielded striking statistical metrics within this cohort:

• Sensitivity: 77 percent
• Specificity: 81 percent
• Positive Predictive Value (PPV): 92 percent
• Negative Predictive Value (NPV): 53 percent
• Overall Accuracy: 78 percent

For comparison within the same study cohort, the overall accuracy stood at 76 percent for the serum albumin-to-globulin ratio, 75 percent for serology, and 69 percent for RT-PCR.

Surprising Revelations in Cellular Load

One of the most unexpected findings of the study was the low threshold required to achieve diagnostic significance. Dr. Evans admitted surprise when data revealed that the presence of a single dual-positive cell was enough to maximize overall accuracy.

"Literally a single virus-infected cell was enough information to discriminate FIP versus non-FIP disease," Dr. Evans says. "It was surprising to me that little material was clinically significant."

Furthermore, performance metrics varied based on the type of sample and clinical presentation. MF-ICC demonstrated heightened sensitivity when performed on effusion fluids, though specificity was occasionally higher in tissue cytology samples from noneffusive FIP cases—a vital asset given that dry FIP cases are historically the most difficult to resolve.

Importantly, the researchers caution against viewing MF-ICC as a sweeping replacement for PCR. The assays frequently identified different individual patients within the study group.

"MF-ICC picked up some FIP cases that PCR did not, and PCR picked up some FIP cases that MF-ICC did not," Dr. Evans points out. "There is value to ordering both. You’ll have a greater chance of picking up an FIP case by submitting both, and the same sample type can be used for these different assays in a complementary way."

Official Statements: Perspectives from the Front Lines of Veterinary Internal Medicine

The implications of this diagnostic advancement extend far beyond the laboratory bench, directly impacting daily veterinary practice and patient outcomes.

Dr. Petra Černá, PhD, DACVIM (SAIM), Dipl. ECVIM-CA, DABVP (Feline), MANZCVS, an assistant professor of small animal internal medicine at the University of Georgia and co-author of the study, highlights the dangerous consequences of diagnostic delays and empirical guesswork.

"It is very important to have access to fast and accurate diagnostic tests so we can confidently treat these cats," Dr. Černá stresses. "Very often, I see cases that have been treated for several weeks with antiviral therapy, and they do not have FIP. That is not good antiviral stewardship, but we are also missing the actual diagnosis and are not able to help these patients."

For primary care veterinarians managing complex caseloads, MF-ICC introduces a practical safety net. When cytology samples have already been collected, when insufficient material remains for RT-PCR, or when molecular tests return negative results despite persistent clinical suspicion, MF-ICC offers an alternative investigative avenue.

"I think this test is another helpful tool in our toolbox to feel more confident about FIP diagnosis," Dr. Černá notes. "No single test is perfect, and the more possibilities we have, the better we can diagnose these cats and treat them appropriately."

Echoing the necessity of speed, Dr. Curtis emphasizes the temporal constraints clinicians face when managing critically ill feline patients. In severe systemic cases, clinical teams may have days—rather than weeks—to initiate intervention.

"Having something with a rapid turnaround is going to be life and death for a lot of cats," Dr. Curtis says. "Being able to get a rapid answer lets owners and veterinarians know whether we need to start moving on treatment or make other decisions."

Future Outlook: Transitioning to Diagnostic Systems and Addressing Comorbidities

As veterinary medicine enters this new era, the integration of laboratory assays into comprehensive diagnostic ecosystems is paramount. MF-ICC is not currently designed as an in-clinic, point-of-care rapid test; it demands specialized laboratory equipment to concentrate cells onto slides, specialized fluorescent reagents, and board-certified veterinary pathologist expertise to interpret complex staining patterns.

Building a Diagnostic Suite at Colorado State University

To maximize clinical accessibility, CSU’s Veterinary Diagnostic Laboratory intends to offer MF-ICC not as an isolated test, but as part of a comprehensive FIP diagnostic service package. This multi-tiered approach will seamlessly integrate MF-ICC, RT-PCR, albumin-to-globulin ratios, and biochemical profiles.

Simultaneously, Dr. Evans’ research group is spearheading the development of machine-learning algorithms designed to analyze routine complete blood counts (CBC) and serum biochemistry panels to flag suspicious patterns early. Backed by CSU’s dedicated FIP biobank and digital repository, these tools will undergo continuous retrospective evaluation as field data accumulates.

Furthermore, the foundational methodology behind MF-ICC is not proprietary. Dr. Curtis notes that veterinary diagnostic laboratories equipped with the appropriate fluorescent microscopy hardware and technical expertise can readily acquire the described antibodies and reagents, paving the way for broader institutional adoption, reduced shipping times, and faster turnaround for practitioners nationwide.

Emerging Challenges in Post-Treatment Feline Health

While improved diagnostics refine the initiation of care, researchers warn that the veterinary community must now confront a new wave of post-treatment complexities. Dr. Černá emphasizes that future research must focus heavily on patient subsets that fail to respond as expected, including critically ill cats battling severe systemic inflammation, suspected viral sepsis, immune-mediated hemolytic anemia, myocarditis, and concurrent infectious diseases.

"We still lose some cats," Dr. Černá observes. "Learning how to best manage these comorbidities to improve prognosis is crucial."

Additionally, long-term epidemiological follow-up is becoming an urgent necessity. As thousands of treated cats achieve durable remissions, clinicians are beginning to document long-term sequelae—such as lingering gastrointestinal disorders and, in isolated reports, large-cell lymphoma. These emerging phenomena raise critical questions regarding long-term post-treatment health that were previously impossible to study when FIP was universally fatal.

Ultimately, the overarching message for veterinary practitioners remains grounded in clinical pragmatism. FIP is no longer an automatic death sentence, but confirming its presence requires rigorous, multi-faceted evidence rather than blind reliance on any single biomarker.

"There’s no perfect test for FIP," Dr. Evans concludes. "One piece is PCR, one is MF-ICC, and this new test is one part of putting together that puzzle."

About the Author

A graduate of the University of Miami, Keith Loria is a D.C.-based, award-winning journalist who has been writing for major publications for close to 20 years on topics as diverse as veterinary medicine, travel, and entertainment. Loria started his career with the Associated Press and has held senior editorial positions at publications focused on healthcare, sports, and technology.